Creative Planning Has $1.65 Million Position in Insulet Co. (NASDAQ:PODD)

Creative Planning trimmed its holdings in Insulet Co. (NASDAQ:PODD) by 4.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,108 shares of the medical instruments supplier’s stock after selling 322 shares during the quarter. Creative Planning’s holdings in Insulet were worth $1,654,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in PODD. Ayrshire Capital Management LLC bought a new stake in Insulet in the third quarter worth approximately $3,975,000. Shaker Investments LLC OH acquired a new stake in shares of Insulet during the 3rd quarter worth approximately $2,563,000. Exchange Traded Concepts LLC bought a new stake in shares of Insulet in the 3rd quarter valued at $121,000. Livforsakringsbolaget Skandia Omsesidigt lifted its position in shares of Insulet by 500.0% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 600 shares of the medical instruments supplier’s stock valued at $139,000 after acquiring an additional 500 shares during the period. Finally, Wedmont Private Capital lifted its position in shares of Insulet by 3.5% during the 3rd quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier’s stock valued at $326,000 after acquiring an additional 48 shares during the period.

Analysts Set New Price Targets

Several equities research analysts have weighed in on PODD shares. UBS Group lifted their price target on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Barclays boosted their target price on Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a research report on Monday, August 12th. BTIG Research increased their price target on Insulet from $250.00 to $260.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Piper Sandler boosted their price objective on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a report on Tuesday, September 17th. Finally, Citigroup increased their target price on Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a report on Tuesday, October 1st. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $242.29.

Insulet Stock Performance

Shares of PODD stock opened at $232.37 on Wednesday. Insulet Co. has a one year low of $128.68 and a one year high of $243.98. The company has a market cap of $16.29 billion, a P/E ratio of 42.25, a P/E/G ratio of 4.36 and a beta of 1.21. The firm has a 50-day moving average of $224.27 and a 200-day moving average of $200.35. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing the consensus estimate of $0.56 by ($0.01). Insulet had a net margin of 21.11% and a return on equity of 30.73%. The firm had revenue of $488.50 million during the quarter, compared to analysts’ expectations of $488.00 million. During the same quarter last year, the business posted $0.38 EPS. The company’s quarterly revenue was up 23.2% on a year-over-year basis. Equities research analysts forecast that Insulet Co. will post 3.04 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.